Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin

被引：130

作者：

Herman, G. A. ^{[1
]}

Stein, P. P. ^{[1
]}

Thornberry, N. A. ^{[1
]}

Wagner, J. A. ^{[1
]}

机构：

[1] Merck Res Labs, Rahway, NJ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷 / 05期

关键词：

D O I：

10.1038/sj.clpt.6100167

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Dipeptidyl peptidase-4 ( DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. 1 DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. 1 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.

引用

收藏

页码：761 / 767

页数：7

相关论文

共 40 条

[31] Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers [J].

Nauck, MA ;

Heimesaat, MM ;

Behle, K ;

Holst, JJ ;

Nauck, MS ;

Ritzel, R ;

Hüfner, M ;

Schmiegel, WH .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1239-1246

[32] NORMALIZATION OF FASTING HYPERGLYCEMIA BY EXOGENOUS GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS [J].

NAUCK, MA ;

KLEINE, N ;

ORSKOV, C ;

HOLST, JJ ;

WILLMS, B ;

CREUTZFELDT, W .

DIABETOLOGIA, 1993, 36 (08) :741-744

[33] Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats [J].

Pospisilik, JA ;

Martin, J ;

Doty, T ;

Ehses, JA ;

Pamir, N ;

Lynn, FC ;

Piteau, S ;

Demuth, HU ;

McIntosh, CHS ;

Pederson, RA .

DIABETES, 2003, 52 (03) :741-750

[34] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus [J].

Raz, I. ;

Hanefeld, M. ;

Xu, L. ;

Caria, C. ;

Williams-Herman, D. ;

Khatami, H. .

DIABETOLOGIA, 2006, 49 (11) :2564-2571

[35] Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice [J].

Reimer, MK ;

Holst, JJ ;

Ahrén, B .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :717-727

[36] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study [J].

Rosenstock, Julio ;

Brazg, Ronald ;

Andryuk, Paula J. ;

Lu, Kaifeng ;

Stein, Peter .

CLINICAL THERAPEUTICS, 2006, 28 (10) :1556-1568

[37]

RUDDY MK, 2006, DIABETES S1, V55, pA715

[38] Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes [J].

Scott, R. ;

Wu, M. ;

Sanchez, M. ;

Stein, P. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (01) :171-180

[39] Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients [J].

Vilsboll, T ;

Krarup, T ;

Deacon, CF ;

Madsbad, S ;

Holst, JJ .

DIABETES, 2001, 50 (03) :609-613

[40] Dipeptidyl peptidase IV inhibitors for the treatment of diabetes [J].

Weber, AE .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) :4135-4141

← 1 2 3 4 →